Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

58.44
-1.5600-2.60%
Post-market: 58.500.0600+0.10%18:50 EDT
Volume:2.08M
Turnover:122.56M
Market Cap:11.29B
PE:154.20
High:60.16
Open:59.81
Low:58.39
Close:60.00
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.11
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.79
PE(LYR):32.47

Loading ...

BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration

Simply Wall St.
·
Yesterday

Biomarin Pharmaceutical Enters Settlement and License Agreement with Ascendis Pharma on Sept 24, 2026

Reuters
·
Yesterday

Biomarin Pharmaceutical - Co and Ascendis to Dismiss All Pending Litigation with Prejudice - SEC Filing

THOMSON REUTERS
·
Yesterday

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% US, 18% EU/Br/SK Royalty on Sales Until May 2030 - SEC Filing

THOMSON REUTERS
·
Yesterday

Biomarin Pharmaceutical - Grants Ascendis License for Transcon Cnp, Navepegritide, Yuviwel - SEC Filing

THOMSON REUTERS
·
Yesterday

BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products

Reuters
·
Yesterday

Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026

Reuters
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Biomarin Pharmaceutical Inc. : JP Morgan Raises Target Price to $86 from $80

THOMSON REUTERS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

BioMarin price target lowered to $97 from $98 at BMO Capital

TIPRANKS
·
Sep 15

BioMarin to discontinue development of Voxzogo for children with Noonan syndrome

TIPRANKS
·
Sep 15

Biomarin Pharmaceutical - Discontinues Development of Voxzogo for Children with Noonan Syndrome on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 15

BioMarin Files Form 3 for Director Robert M. Plenge, Reporting no Beneficial Ownership

Reuters
·
Sep 15

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Biomarin Announces Appointment of Robert Plenge, M.d., Ph.d., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

THOMSON REUTERS
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

BioMarin Pharmaceutical Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

TIPRANKS
·
Sep 09